Asieris(SH:688176)2025-01-17 09:50Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between -436.92 million and -366.07 million CNY, representing a year-on-year increase in losses of 9.11% to a decrease of 8.58%[4]. - The projected operating revenue for 2024 is approximately 176.49 million to 211.79 million CNY, an increase of 1,183.27% to 1,439.92% compared to the previous year[6]. - The company's total profit for 2023 was -401.50 million CNY, with a net profit attributable to shareholders of -400.43 million CNY[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2023 was -432.22 million CNY[8]. - The financial data provided is preliminary and subject to final audit in the 2024 annual report[12]. - There are no significant uncertainties affecting the accuracy of this earnings forecast[11]. Research and Development - Research and development expenses for 2024 are estimated to be between 296.90 million and 354.36 million CNY, a decrease of 18.57% to 2.81% from the previous year[6]. - The estimated decrease in R&D expenses is influenced by lower clinical trial costs and preclinical research expenses[9]. Revenue Drivers - The increase in operating revenue for 2024 is primarily driven by the commercialization of Pazopanib tablets and Neralitinib tablets, which began in Q4 2023[9]. - The company anticipates a decrease in non-recurring gains and losses, mainly due to reduced government subsidies compared to the previous year[9].